Shilpa Medicare Ltd's Q4FY25 Quarter Results
- 27 May 2025
Result Summary
- Shilpa Medicare Ltd reported a 8.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 10.7%.
- Its expenses for the quarter were down by 2.4% QoQ and up 1.4% YoY.
- The net profit decreased 22.9% QoQ and decreased 404.7% YoY.
- The earnings per share (EPS) of Shilpa Medicare Ltd stood at 2.8 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 294.19 | 320.45 | 265.73 | -8.2% | 10.7% |
Total Expenses | 272.46 | 279.18 | 268.77 | -2.4% | 1.4% |
Profit Before Tax | 27.85 | 41.27 | -3.03 | -32.5% | -1019.1% |
Tax | 3.21 | 9.83 | 3.82 | -67.3% | -16.0% |
Profit After Tax | 24.50 | 31.78 | -8.04 | -22.9% | -404.7% |
Earnings Per Share | 2.80 | 3.30 | -0.90 | -15.2% | -411.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Shilpa Medicare Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the manufacturing and marketing of pharmaceutical products. The company specializes in generic formulations and active pharmaceutical ingredients (APIs), catering to both domestic and international markets. Shilpa Medicare has a significant presence in the oncology segment, which is one of its key areas of expertise. It is known for its capabilities in complex generics and innovative drug delivery systems. As of the latest data available up to October 2023, there are no specific recent major developments reported for the company.
Revenue
The financial performance of Shilpa Medicare Ltd for the fourth quarter of fiscal year 2025 (Q4FY25) shows that the company achieved a total income of ₹294.19 crores. This represents a decline of 8.2% from the previous quarter (Q3FY25), where the total income was ₹320.45 crores. However, when compared to the same quarter of the previous year (Q4FY24), there is a notable increase of 10.7%, as the total income was ₹265.73 crores at that time. These figures reflect the company's ability to generate revenue over different periods, indicating fluctuations in its income streams.
Profitability
In terms of profitability, Shilpa Medicare Ltd reported a Profit Before Tax (PBT) of ₹27.85 crores for Q4FY25. This shows a significant decrease of 32.5% when compared to the previous quarter, where PBT was ₹41.27 crores. On a year-over-year basis, the change is even more pronounced, showing an improvement from a negative PBT of ₹-3.03 crores in Q4FY24. The Profit After Tax (PAT) for Q4FY25 was ₹24.50 crores, which is a decrease of 22.9% from Q3FY25's PAT of ₹31.78 crores, but a substantial improvement from the loss of ₹-8.04 crores in Q4FY24. Earnings Per Share (EPS) followed a similar trend, recorded at ₹2.80 for Q4FY25, down 15.2% from Q3FY25, but significantly up from the negative EPS of ₹-0.90 in Q4FY24.
Operating Metrics
The total expenses for Shilpa Medicare Ltd in Q4FY25 were ₹272.46 crores, which is a 2.4% decrease from the previous quarter's expenses of ₹279.18 crores. Compared to the same quarter in the previous year, the expenses increased marginally by 1.4%, from ₹268.77 crores in Q4FY24. The tax expense for Q4FY25 was ₹3.21 crores, which is a substantial reduction of 67.3% from Q3FY25's tax expense of ₹9.83 crores and a 16.0% decrease from ₹3.82 crores in Q4FY24. These operating metrics provide insights into the company's cost management and tax implications over different periods.